Deucravacitinib (Sotyktu) is a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor, FDA-approved in September 2022 for moderate-to-severe plaque psoriasis. It is the first novel oral therapy for this indication in nearly 10 years, and is believed to potentially become the new standard of care. Deucravacitinib is the first de [...]
4 minute read
Mar. 13, 2023
Deucravacitinib: a First-In-Class Oral, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor
BMS TYK2 inhibitor
first-in-class oral, allosteric TYK2 inhibitor FDA-approved for moderate-to-severe plaque psoriasis opt. + SBDD of in-house phenotypic HTS hit deucravacitinib (BMS-986165, SOTYKTU) Bristol Myers Squibb, New York, NY